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In this issue of Chemistry & Biology, Arrendale and coworkers demonstrate a new prodrug strategy for
intracellular delivery of an a, a-(difluoromethylene)phosphonate phosphoserine mimic. The deprotected
pseudo-phosphopeptide releases the pro-apoptotic FOXO3a-transcription factor from its 14-3-3-adaptor
protein complex, resulting in leukemic cell death.Signal transduction in nature often in-
volves protein phosphorylation. The com-
bination of kinetic stability and thermody-
namic lability of the phosphate ester
renders it an excellent switch. Much of
the kinetic stability to nucleophilic attack
presumably derives from the negatively
charged phosphoryl oxygens in its pre-
dominantly dianionic form (pKa2 6.5).
Because of the ubiquity of phosphoryla-
tion as a signaling mechanism, chemical
biologists have long sought to synthesize
compounds that structurally and func-
tionally mimic phosphate ester function-
ality but are resistant to phosphatase
cleavage. Replacing the bridging oxygen
with carbon confers such resistance,
but simple CH2-bridged phosphonates
have an elevated second pKa (7–7.5),
exhibiting considerable monoanionic
character. However, upon a-fluorination,Figure 1. Fluorinated Phosphonates versus Phosphates:
A Computational Comparison
Electrostatic potential (ESP) maps were generated from DFT calculations with
Gaussian 03W using the B3LYP function at the 6-311+g(d,p) level. Calcula-
tions were performed on full ground state optimizations, plus frequencies.
ESP maps were generated in Gaussview 3.0. Isosurfaces were generated
with a total charge density of 0.0004 e/bohr. Note that the charge distribution
shown is for the minimum energy conformer located. At room temperature,
rapid single bond rotation should lead to equal charge distribution across
the three anionic phosph(on)ate oxygens.the second pKa successively
decreases in going from a
CHF- (pKa 6–6.5) to a CF2-
bridge (pKa 5–5.5). At the
same time, C-C(H)(F)-P bond
angle increases [e.g., from
112 (CH2) to 113 (CHF) to
117 (CF2) in a series studied
by Nieschalk et al. (1996)],
reaching an angle very close
to the native C-O-P angle
(119) for the difluorinated
phosphonate.
Such considerations led
(Caplan et al. (2000) and
others to regarda,a-(difluoro-
methylene)phosphonates as
‘‘isopolar’’ and ‘‘isosteric’’
phosphate analogs. While the
CF2-bridge clearly projects
a larger van der Waals radius
than the native bridging O,
the fact that it expands the
C-CF2-P bond angle lends666 Chemistry & Biology 19, June 22, 2012 ªsome merit to the label ‘‘isosteric.’’ The
‘‘isopolar’’ nature of this functionality, on
the other hand, is supported by DFT
calculations on simple model compounds
(Figure 1). The partial charge on the
bridging phosphate ester oxygen
(0.453) is mimicked by the bridging
CF2-phosphonate carbon (0.395), espe-
cially when one considers the additional
charge density on the pendant fluorines
(0.172 each).
Accordingly, in the 1990s, our group
developed CF2-phosphonate analogs of
pSer and pThr (Berkowitz et al., 1996,
1999) as tools for the study of protein
phosphorylation (abbreviated pCF2-Ser;
Panigrahi et al., 2009). Recent years
have seen the very creative application
of these tools. One particularly compelling
use is to modulate protein-protein inter-
actions (PPIs) that depend upon Ser/2012 Elsevier Ltd All rights reservedThr phosphorylation. Paramount among
these are the interactions of 14-3-3
adaptor proteins, ubiquitous ‘‘chaper-
ones’’ that bind to phosphorylated partner
proteins to modulate signal transduction,
the cell cycle, intracellular trafficking and
transcription.
Obsil et al. (2001) solved a prototypical
14-3-3-adaptor/phosphorylated-partner
protein complex structure. The struc-
ture reveals in beautiful molecular detail
how the phosphothreonine residue of
the AANAT is tightly bound at a groove
in the 14-3-3 dimer interface that is rich
in H-bond donating residues, Y128, R86,
and R127, resulting in a ‘‘molecular
Velcro’’-like interaction. The two arginine
residues also appear to electrostatically
pair with the pThr dianion, making this
an ideal site to target with the CF2-
phosphonate functionality.With the appearance of the
paper in this issue of Chem-
istry & Biology by Arrendale
et al. (2012), now two comple-
mentary approaches exist
that, taken together, attest to
the abililty of pCF2-Ser-
bearing ligands to modulate
14-3-3-mediated PPIs.
In earlier work, Zheng et al.
(2005) modified the native
protein itself, AANAT, using
expressed protein ligation
(EPL) technique to graft the
phosphatase-inert pCF2-Ser
residue onto position 205
of the wild-type protein. This
effectively leads to a ‘‘con-
stitutively phosphorylated’’
AANAT, remaining closely
associated with its 14-3-3-
zeta binding partner, and
thereby stabilizing the protein
to proteasomal degradation.
Figure 2. Prodrug Release Mechanism
Depicted is the putative mechanism of intracellular prodrug activation, under reductive conditions, for the
pCF2-Ser-containing dipeptide ligand for the 14-3-3 adapter protein.
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cells, Zheng et al. (2005) saw the persis-
tence of this tight pCF2-Ser/14-3-3 inter-
action under intracellular conditions.
Very recently, Tarrant et al. (2012) have
shown that this same strategy can be ex-
ploited to stabilize the important signal-
transducing casein kinase II (CK2) kinase
involved in cell proliferation. In this case,
the PPI being targeted involves the CK2
interaction with the regulatory protein,
Pin1. The CK2-Pin1 association is
promoted by phosphorylation of Thr-344.
Again utilizing EPL to incorporate pCF2-
Ser at this site, Tarrant et al. (2012) were
able to show that the semisynthetic CK2
binds tightly to its Pin1 regulatory protein
partner, and that this interaction both
stabilizes the protein to proteasomal
degradation and alters its polypeptide
substrate specificity.
Herein, Arrendale et al. (2012) first re-
ports a new, efficient stereocontrolled
synthesis of the pCF2-Ser building block,
utilizing a nice stereo-retentive aziridine-
opening. Arrendale et al. (2012) then
truly open up a new vista in the applica-
tion of this chemical biological tool by
installing one of their trademark prodrug
functionalities onto the fluorinated phos-
phonate and using this to deliver a
carefully crafted pCF2-Ser-containingdipeptide ligand for the 14-3-3 adaptor
protein into the cell.
The elegant presumptive phosphonate
release mechanism is depicted in Fig-
ure 2. The 50-nitrofuryl-20-methyl N(400-
chlorobutyl)phosphonamido ester pro-
drugging strategy masks the fluorinated
phosphonate as a neutral non-polar deriv-
ative, and subsequently promotes its
release under reducing conditions within
the cell. Reductive cleavage of the phos-
phonate ester, and subsequent ioniza-
tion places more electron density on the
amide nitrogen, permitting a Baldwin’s
rules-favored 5-exo-tet cyclization to a
pyrrolidinium ring, also an excellent leav-
ing group. Hydrolysis and ionization then
give the free phosphonate dianion.
In the case at hand, the released modi-
fied dipeptide ligand successfully com-
petes, in vivo, with the phosphorylated
FOXO3a transcription factor for its 14-
3-3 adaptor protein, thereby effectively
titrating off the adaptor at micromolar
ligand concentrations. Applied to leu-
kemia cells, the authors show that this
14-3-3-sequestering strategy can be
used to induce the pro-apoptotic effects
of the free FOXO3a protein, with atten-
dant anti-leukemic activity.
These studies expand the domain in
which such ‘‘teflon phosphates’’ may beChemistry & Biology 19, June 22, 2012deployed to ask fundamental questions
in chemical biology, allowing for their
transport into the cell. Given recent ex-
citing developments in photocaging/
release of native pSer functionality from
the Imperiali lab (Goguen et al., 2011), it
will be interesting to see if this strategy
can be expanded to include wavelength
specific photolabile prodrug function-
alities for pCF2Ser. One can imagine
thusly asking more finely tuned questions
relating to the temporal regulation of pro-
tein function via phosphorylation. Clearly,
given the abundance of 14-3-3 adaptor
protein-mediated regulatory interactions,
both this work and the complementary
protein-grafting work in the Cole group
open up important horizons for the inter-
rogation of phosphorylation-dependent
PPIs with this chemical biological tool.
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